COVID-19 medical management including World Health Organization (WHO) suggested management strategies

McFee, Robin B.

doi:10.1016/j.disamonth.2020.101068

Cited by 24 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SARS-CoV-2 outbreak was identified at Wuhan in December 2019, and the worldwide diagnosis of SARS-CoV-2 is now 21 century pandemic 18 . Globally, 111,279,860 confirmed cases of COVID-19 were reported to WHO on 23 February 2021, including 2,466,639 deaths.…”

Section: Discussionmentioning

confidence: 99%

Characterization of the SARS-CoV-2 genomes in Egypt in first and second waves of infection

Zekri

Bahnasy

Hafez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

At Wuhan, in December 2019, the SRAS-CoV-2 outbreak was detected and it has been the pandemic worldwide. This study aims to investigate the mutations in sequence of the SARS-CoV-2 genome and characterize the mutation patterns in Egyptian COVID-19 patients during different waves of infection. The samples were collected from 250 COVID-19 patients and the whole genome sequencing was conducted using Next Generation Sequencing. The viral sequence analysis showed 1115 different genome from all Egyptian samples in the second wave mutations including 613 missense mutations, 431 synonymous mutations, 25 upstream gene mutations, 24 downstream gene mutations, 10 frame-shift deletions, and 6 stop gained mutation. The Egyptian genomic strains sequenced in second wave of infection are different to that of the first wave. We observe a shift of lineage prevalence from the strain B.1 to B.1.1.1. Only one case was of the new English B.1.1.7. Few samples have one or two mutations of interest from the Brazil and South Africa isolates. New clade 20B appear by March 2020 and 20D appear by May 2020 till January 2021.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of the SARS-CoV-2 genomes in Egypt in first and second waves of infection

Zekri

Bahnasy

Hafez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The severe pneumonia was defined with any of the following in patients with laboratory and thorax CT-confirmed interstitial pneumonia: (1) respiratory distress (respiratory rate ≥ 30 breaths per min); (2) oxygen saturation at rest ≤ 93%; (3) ratio of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen inspired air (FiO2) (PaO2:FiO2, ≤ 300 mmHg); or (4) a critical complication (respiratory failure and mechanical ventilation required, septic shock, and/or multiple organ dysfunction/failure and intensive care unit admission required) [ 16 ].…”

Section: Methodsmentioning

confidence: 99%

Impairment of right ventricular longitudinal strain associated with severity of pneumonia in patients recovered from COVID-19

Özer

Gövdeli

Baykız

et al. 2021

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

Myocardial injury caused by COVID-19 was reported in hospitalized patients previously. But the information about cardiac consequences of COVID-19 after recovery is limited. The aim of the study was comprehensive echocardiography assessment of right ventricular (RV) in patients recovered from COVID-19. This is a prospective, single-center study. After recovery from COVID-19, echocardiography was performed in consecutive 79 patients that attended follow-up visits from July 15 to November 30, 2020. According to the recovery at home vs hospital, patients were divided into two groups: home recovery (n = 43) and hospital recovery (n = 36). Comparisons were made with age, sex and risk factor-matched control group (n = 41). In addition to conventional echocardiography parameters, RV global longitudinal strain (RV-GLS) and RV free wall strain (RV-FWS) were determined using 2D speckle-tracking echocardiography (2D STE). Of the 79 patients recovered from COVID-19, 43 (55%) recovered at home, while 36 (45%) required hospitalization. The median follow-up duration was 133 ± 35 (87–184) days. In patients recovered from hospital, RV-GLS and RV-FWS were impaired compared to control group (RV-GLS: −17.3 ± 6.8 vs. −20.4 ± 4.9, respectively [p = 0.042]; RV-FWS: −19.0 ± 8.2 vs. −23.4 ± 6.2, respectively [p = 0.022]). In subgroup analysis, RV-FWS was impaired in patients severe pneumonia (n = 11) compared to mild-moderate pneumonia (n = 28), without pneumonia (n = 40) and control groups (−15.8 ± 7.6 vs. −21.6 ± 7.6 vs. −20.8 ± 7.7 vs. −23.4 ± 6.2, respectively, [p = 0.001 for each]) and RV-GLS was impaired compared to control group (−15.2 ± 6.9 vs. −20.4 ± 4; respectively, [p = 0.013]). A significant correlation was detected between serum CRP level at hospital admission and both RV-GLS and RV-FWS (r = 0.285, p = 0.006; r = 0.294, p = 0.004, respectively). Age (OR 0.948, p = 0.010), male gender (OR 0.289, p = 0.009), pneumonia on CT (OR 0.019, p = 0.004), and need of steroid in treatment (OR 17.424, p = 0.038) were identifed as independent predictors of impaired RV-FWS (> −18) via multivariate analysis. We demonstrated subclinic dysfunction of RV by 2D-STE in hospitalized patients in relation to the severity of pneumonia after recovery from COVID-19. 2D-STE supplies additional information above standard measures of RV in this cohort and can be used in the follow-up of these patients.

show abstract

“…To date, there have been confirmed cases of COVID-19 and asymptomatic infections in several provinces and cities, including Hebei and Guangdong. At present, strengthening the prevention and control of nosocomial infection, reducing the occurrence of nosocomial infection as much as possible, and enabling the early identification and isolation of asymptomatic cases and confirmed cases are the top priorities for controlling the source of infection and reducing the incidence of disease [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial

Gong

Yuan

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a global pandemic. Community and close contact exposures continue to drive the COVID-19 pandemic. There is no confirmed effective treatment for suspected cases and close contacts. Lianhuaqingwen (LH) capsules, a repurposed Chinese herbal product that is currently on the market, have proven effective for influenza and COVID-19. To determine the safety and efficacy of LH capsules for the prevention of COVID-19, we conducted a prospective open-label controlled trial of LH capsules on subjects who had close contact with people infected with COVID-19. Subjects received LH capsules (4 capsules, three times daily) or the usual medical observation for 14 days. The primary endpoint was the rate of positive nucleic acid tests of nasal and pharyngeal swabs during the quarantine medical observation period. We included 1976 patients, including 1101 in the treatment group and 875 in the control group. The rate of positive nucleic acid tests in the treatment group was significantly lower than that in the control group (0.27% vs. 1.14%, respectively; mean difference: −0.87%; 95% CI: −1.83 to −0.13; p = 0.0174 ) during the quarantine medical observation period (14 days). Among subjects with different close contact states, there was no significant difference in the rate of positive nucleic acid test results among close contacts in the treatment group and the control group (6.45% vs. 11.43%, respectively; p = 0.6762 ). Among secondary close contacts, the rate of positive nucleic acid tests in the treatment group was significantly lower than that in the control group (0.09% vs. 0.71%, respectively; p = 0.0485 ). No serious adverse events were reported. Taken together, and in light of the safety and effectiveness profiles, these results show that LH capsules can be considered to prevent the progression of COVID-19 after close contact with an infected person. This trial is registered with ChiCTR2100043012.

show abstract

COVID-19 medical management including World Health Organization (WHO) suggested management strategies

Cited by 24 publications

References 54 publications

Characterization of the SARS-CoV-2 genomes in Egypt in first and second waves of infection

Characterization of the SARS-CoV-2 genomes in Egypt in first and second waves of infection

Impairment of right ventricular longitudinal strain associated with severity of pneumonia in patients recovered from COVID-19

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial

Contact Info

Product

Resources

About